



Name	Sophie Paczesny
Current Position	Professor and Chair, Department of Microbiology and Immunology, Medical University of South Carolina
Country	USA
Major Field	Proteomics, biomarkers, GVHD ST2/IL33 axis, T cells biology

Educational Background

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date YYYY	FIELD OF STUDY
University of Strasbourg, France	MD	1995	Medicine
Hospitals of Paris, Paris, France	Residency/Fellowship	2000	Pediatric Hematology/Oncology
Baylor Institute for Immunology Research, Dallas, TX	Fellowship	2003	Immunotherapy and Cancer Vaccines
University of Paris VI, France	PhD	2004	Tumor Immunology
Fred Hutchinson Cancer Research Center, Seattle, WA	Visiting Scientist	2008	Clinical Proteomics
University of Michigan, Ann Arbor, MI	Fellowship	2009	Proteomics/Biomarkers/Hematopoietic Cell Transplantation

Professional Experience

2003 – 2005	Assistant Professor, University and Hospital of Nancy, Nancy, France
2007 – 2008	Visiting Scientist, Fred Hutchinson Cancer Research Center
2009 – 2012	Assistant Professor tenure-track, Department of Pediatrics, University of Michigan
2012 – 2015	Associate Professor, Department of Pediatrics and Immunology, Indiana University
2015 – 2020	Tenured Professor, Department of Pediatrics and Immunology, Indiana University
2020 – Present	Professor and Chair of the Department of Microbiology and Immunology Medical University of South Carolina, Charleston, SC
2020 – Present	Sally Abney Rose Endowed Chair in Cancer Stem Cell Biology, Medical University of South Carolina, Charleston, SC
2023 – Present	Hollings Cancer Center Cancer Biology & Immunology Program co-leader, Medical University of South Carolina, Charleston, SC

Other Experience and Professional Memberships

2018 – 2023	Co-chair Immunobiology CIBMTR Working Group
2018 – 2019	Metabolic Reprogramming to Improve Immunotherapy Special Emphasis Panel Study Section
2019	Pediatric Immunotherapy Discovery and Development Network (PI-DDN) Study Section
2019 – 2020	NCI Program Project II (P01) Study Section, CII Study section ad hoc member
2021	CONC Study Section standing member
2019 – 2022	Elected American Society for Clinical Investigation (ASCI) Councilor
2021 – 2023	Chair, ASCI Diversity, Equity, and Inclusion Committee

Main Scientific Publications

- Vander Lugt MT, Braun T, Hanash S, Ferrara JLM, Ritz J., Ho VT., Antin JH., Zhang Q, Wong CH., Wang H., Chin A, Gomez A, Harris AC, Levine JE, Choi SW, Couriel D, Reddy P and **Paczesny S**. ST2 as a marker for risk of the therapy-resistant graft-versus-host disease and death. *New England Journal Medicine* 2013 August 8; 369(6):529-39. PMID: PMC3943357.
- Zhang J, Ramadan A, Griesenauer B, Li W, Turner M, Liu C, Kapur R., Hanenberg H., Blazar BR, Tawara I, and **Paczesny S**. ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease. *Sci Transl Med* 2015, 7(308): 308ra160. PMID: PMC4699312.
- Ramadan AM, Daguindau E, Rech JC, Chinnaswamy K, Zhang J, Hura GL, Griesenauer B, Bolten Z, Robida A, Larsen M, Stuckey JA, Yang CY, **Paczesny S**. From proteomics to discovery of first-in-class ST2 inhibitors active in vivo. *Journal of Clinical Investigation Insight*. 2018 Jul 25;3(14). PMID: PMC6124397.
- Yu J, Storer B, Kushekhar K, Abu Zaid M, Zhang Q, Gafken PR, Ogata Y, Martin PJ, Flowers ME, Hansen JA, Arora M, Cutler C, Jagasia M, Pidala J, Hamilton BK, Chen GL, Pusic I, Lee SJ, and **Paczesny S**. A biomarker panel for chronic graft-versus-host disease. *The Journal of Clinical Oncology*, 2016 May 23. PMID: PMC5012688.
- Forcade E, Paz K, Flynn R, Griesenauer B, Amet T, Li W, Liu L, Bakoyannis G, Jiang D, Chu HW, Lobera M, Yang J, Wilkes DS, Du J, Gartlan K, Hill GR, MacDonald KP, Espada EL, Blanco P, Serody JS, Koreth J, Cutler CS, Antin JH, Soiffer RJ, Ritz J, Paczesny S, Blazar BR. An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition. *Journal of Clinical Investigation Insight*. 2017 Jun 15;2(12). PMID: PMC5470889.
- Ramadan A, Griesenauer B, Adom D, Kapur R, Hanenberg H, Liu C, Kaplan MH, and **Paczesny S**. Specifically Differentiated T Cell Subset Promotes Tumor Immunity over Fatal Immunity. *Journal of Experimental Medicine*, 2017 Dec 4;214(12):3577-3596. PMID: PMC5716032. * **This paper has been cited and highlighted in the New England Journal of Medicine.**
- Rowan C, Pike F, Cooke KR, Krance R, Carpenter PA, Duncan C, Jacobsohn DA, Bollard CM, Cruz CRY, Malatpure A, Farag SS, Renbarger J, Liu H, Bakoyannis G, Hanash S, **Paczesny S**. Assessment of ST2 for risk of death following graft-versus-host disease in the pediatric and adult age groups. *Blood*. 2020 Apr 23;135(17):1428-1437. doi: 10.1182/blood.2019002334. PMID: PMC7180084.
- Adom D, Dillon SR, Yang J, Liu H, Ramadan A, Kushekhar K, Hund S, Albright A, Kirksey M, Adeniyani T, Lewis KE, Evans L, Wu R, Levin SD, Mudri S, Yang J, Rickel E, Seaberg M, Henderson K, Gudgeon CJ, Wolfson MF, Swanson RM, Swiderek KM, Peng SL, Hippen KL, Blazar BR, **Paczesny S**. ICOSL⁺ plasmacytoid dendritic cells as inducer of graft-versus-host disease, responsive to a dual ICOS/CD28 antagonist. *Sci Transl Med*. 2020 Oct 7;12(564):eaay4799. PMID: PMC7811191.
- Han Y, Bidgoli A, DePriest BP, Méndez A, Bijangi-Vishehsaraei K, Perez-Albuerna ED, Krance RA, Renbarger J, Skiles JL, Choi SW, Liu H, **Paczesny S**. Prospective assessment of risk biomarkers of sinusoidal obstruction syndrome after hematopoietic cell transplantation. *JCI Insight*. 2023 Apr 18:e168221. doi: 10.1172/jci.insight.168221. Online ahead of print.
- Pasupuleti SK, Ramdas B, Burns SS, Palam LR, Kanumuri R, Kumar R, Pandhiri TR, Dave U, Yellapu NK, Zhou X, Zhang C, Sandusky GE, Yu Z, Honigberg MC, Bick AG, Griffin GK, Niroula A, Ebert BL, **Paczesny S**, Natarajan P, Kapur R. Obesity induced inflammation exacerbates clonal hematopoiesis. *J Clin Invest*. 2023 Apr 18:e163968. doi: 10.1172/JCI163968. Online ahead of print.

ICBMT 2023

THE 7TH INTERNATIONAL CONGRESS OF BMT 2023
28TH ANNUAL CONGRESS OF KSBMT

Exploring New Insights into the Future of HSCT and Cellular Therapy

AUGUST 31(Thu) – SEPTEMBER 2(Sat), 2023

BUSAN, KOREA / OFFLINE CONGRESS

<http://icbmt.or.kr>



ICBMT 2023 Secretariat [People-x.,Inc]

1F, Haeoreum B/D 16, Yeoksam-ro 17 gil, Gangnam-gu, Seoul, 06246, Korea

T. +82-2-566-6031 F. +82-2-566-6087 E. icbmt@icbmt.or.kr

The Korean Society of Blood and Marrow Transplantation KSBMT